ライフサイエンスコーパス: fusidic acid

1 sttranslocational state using the antibiotic fusidic acid.

2 usB bound staphylococcal EF-G, the target of fusidic acid.

3 agents, such as bile acids, novobiocin, and fusidic acid.

4 cter oralis susceptible to metronidazole and fusidic acid.

5 osome complex in a manner similar to that of fusidic acid.

6 . gallinarum isolates were also resistant to fusidic acid.

7 aracterization of MRSA that are resistant to fusidic acid.

8 erhydrophenanthrene, an ABC ring analogue of fusidic acid 1.

9 dissociation, analogous to the mechanism of fusidic acid, a chemically distinct antibiotic that bind

10 The activity of fusidic acid against 778 isolates of Staphylococcus aure

11 e co-crystal structure of HSA complexed with fusidic acid, an antibiotic that competitively displaces

12 In contrast, fusidic acid and a GTP analog that fix EF-G to the ribos

13 stance will likely limit the clinical use of fusidic acid and bacitracin and, possibly, rifaximin if

14 olyticus and S. hominis, whereas penicillin, fusidic acid and erythromycin were the most frequent ant

15 The complexes from which fusidic acid and flufenamic acid were derived would not

16 tetracycline, chloramphenicol, erythromycin, fusidic acid and spectinomycin, do not induce the confor

17 -dependent release occurs in the presence of fusidic acid and viomycin.

18 omial proportion, 0.73 [95% CI, 0.61-0.83]), fusidic acid (binomial proportion, 0.80 [95% CI, 0.62-0.

19 -hydrolyzable GTP analogue GDPNP or GTP plus fusidic acid causes an increase in the efficiency of ene

20 Fusidic acid (CEM-102) is an established antistaphylococ

21 ility testing reagents (including Etest) for fusidic acid (CEM-102) performed at an excellent level o

22 have visualized EF-G in a ribosome-EF-G-GDP-fusidic acid complex.

23 oxacillin and fusidic acid shows binding of fusidic acid deeply inside the T protomer transmembrane

24 dic acid, suggesting that EF-G stabilized by fusidic acid does not represent the natural post-termina

25 DB, and the proposed mechanism of action of fusidic acid, evidence is presented in support of the Gr

26 ed that these mutants interacted weakly with fusidic acid, explaining the mechanism of drug resistanc

27 Fusidic acid (FA) has been used for decades for bone inf

28 Resistance to the antibiotic fusidic acid (FA) in the human pathogen Staphylococcus a

29 omes and to elucidate the mechanism by which fusidic acid (FA) inhibits multiple-turnover EF-G.GTPase

30 rce of clinical resistance to the antibiotic fusidic acid (FA) is expression of the FusB family of pr

31 Fusidic acid (FA) is one of few remaining antibiotics ac

32 The antibiotic fusidic acid (FA) is used to treat Staphylococcus aureus

33 of cholesterol and steroid-based antibiotic fusidic acid (FA) on the behavior of lipid bilayers usin

34 We observed a dramatic increase in fusidic acid (FA) resistance, and clonal expansion of FA

35 The antibiotic fusidic acid (FA) targets elongation factor G (EF-G) and

36 Fusidic acid (FA), an antibiotic used against pathogenic

37 rate recognition of both chloramphenicol and fusidic acid (FA).

38 on one, an FDA-approved natural antibiotic, fusidic acid (FA).

39 coccal translation system from inhibition by fusidic acid in a specific and dose-dependent fashion.

40 d pUB101 capable of conferring resistance to fusidic acid in S. aureus.

41 The antibiotic fusidic acid increases the population of the 0.6 state,

42 activity of a gram-positive-only antibiotic, fusidic acid, into a version that demonstrates a dramati

43 beta-lactams, erythromycin, clindamycin, and fusidic acid may be suboptimal for empirical use in indi

44 nt splitting, while the inhibitory effect of fusidic acid on the splitting was nominal.

45 o 47.9%, P < .001) and a >2-fold increase in fusidic acid resistance (9.0% to 22.5%, P < .001).

46 Although several strains harboured SCC-borne fusidic acid resistance (fusC) (n = 181), erythromycin/c

47 l that the molecular mechanism of antibiotic fusidic acid resistance for EF-G2(mt) is markedly differ

48 a mec B complex was found together with the fusidic acid resistance gene fusC and accompanying genes

49 The primary mechanism of fusidic acid resistance in clinical strains of Staphyloc

50 cture of the complex formed between the FusB fusidic acid resistance protein and the drug target (EF-

51 sing mecA and mupA PCR, respectively, whilst fusidic acid resistance were detected by fusA gene seque

52 tion assays and the frequency of mutation to fusidic acid resistance.

53 shedding light on the molecular mechanism of fusidic acid resistance.

54 erved increases in the number of spontaneous fusidic acid-resistant mutants of five- and sevenfold in

55 aureus harboring mupA, and four isolates of fusidic acid-resistant S. aureus with novel point mutati

56 ma-imidoguanosine 5'-triphosphate (GDPNP) or fusidic acid reveal conformational changes occurring dur

57 xacin, vancomycin, trimethoprim, gentamicin, fusidic acid, rifampin, and mupirocin) performed by the

58 sults were compared with those obtained with fusidic acid, showing that both drugs act in a different

59 ce of erythromycin, linezolid, oxacillin and fusidic acid shows binding of fusidic acid deeply inside

60 did not bind to EF-G-ribosome complexes with fusidic acid, suggesting that EF-G stabilized by fusidic

61 Fusidic acid traps EF-G in a conformation intermediate b

62 beta-lactams used in hospitals as well as to fusidic acid used in the community.

63 but significantly (p < 0.001); resistance to fusidic acid was stable (p > 0.05); resistance to tetrac

64 in provided no protection from inhibition by fusidic acid when added to an in vitro E. coli translati

65 On the other hand, sordarin or fusidic acid, when applied together with eEF2/GTP, speci

66 o identify two compounds-flufenamic acid and fusidic acid-which show strong inhibition of viral repli

67 wo proteins differ in their sensitivities to fusidic acid, with the latter activity inhibited by the